Pharmaceutical Composition for Treating or Preventing Cancer Comprising Inhibitor of NUTM1 and Anticancer Agent as Active Ingredients and Use Thereof

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an inhibitor of NUTM1 expression or activity and an anticancer agent as active ingredients, and a use thereof. More specifically, the present invention provides a therapeutic regimen for NUT carcinoma, which induces the expression of a TROP2 protein by specifically regulating NUTM1 gene expression and utilizes the same as a target for targeted therapy. That is, the NUTM1 inhibitor according to the present invention enhances the responsiveness to a TROP2-targeted anticancer agent, thereby increasing the anticancer effect when administered in combination with the TROP2-targeted anticancer agent. Accordingly, the present invention can enhance the therapeutic effect of the targeted anticancer agent in cancer patients, thereby suggesting a novel therapeutic strategy using the same.

Dependencies are inferred from the claim text.